Baseline Characteristics
| Characteristic | Variable | Data |
| Age (y) | <65 | 104 (56.2) |
| ≥65 | 81 (43.8) | |
| Sex | Male | 148 (80) |
| Female | 37 (20) | |
| Largest tumor size | <5 cm | 50 (27) |
| ≥5 cm | 135 (73) | |
| PVT | Segmental | 43 (23) |
| Lobar | 65 (35) | |
| Main | 77 (42) | |
| Distribution | Solitary | 53 (28.6) |
| Multifocal | 132 (71.4) | |
| Tumor infiltration | Noninfiltrative | 80 (43) |
| Infiltrative | 105 (57) | |
| Tumor location | Unilobar | 107 (57.8) |
| Bilobar | 78 (42.2) | |
| Method of diagnosis | Imaging | 121 (65.4) |
| AFP | 6 (3.2) | |
| Biopsy | 58 (31.4) | |
| ECOG performance status | 0 | 77 (41.6) |
| 1 | 93 (50.3) | |
| 2 | 15 (8.1) | |
| Underlying liver disease | ETOH | 26 (14.1) |
| HCV | 94 (50.8) | |
| HBV | 17 (9.2) | |
| NASH | 6 (3.2) | |
| Unknown | 22 (11.9) | |
| Cryptogenic | 14 (7.6) | |
| Other | 6 (3.2) | |
| Imaging cirrhosis | Present | 164 (88.6) |
| Absent | 21 (11.4) | |
| Ascites | Absent | 123 (66.5) |
| Moderate | 54 (29.2) | |
| Severe | 8 (4.3) | |
| CP | A | 74 (40) |
| B7 | 51 (28) | |
| ≥B8 | 60 (32) | |
| Bilirubin (mg/dL) | <2 | 156 (84.3) |
| 2–3 | 17 (9.2) | |
| >3 | 12 (6.5) | |
| Prior liver-directed therapy | None | 170 (92) |
| Resection | 4 (2.2) | |
| Chemoembolization | 8 (4.3) | |
| Radiofrequency ablation | 3 (1.6) | |
| AFP (ng/mL) | ≤100 | 62 (33.5) |
| >100 | 123 (66.5) | |
| Albumin (mg/dL) | >3.5 | 20 (10.8) |
| 2.8–3.5 | 93 (50.3) | |
| <2.8 | 72 (38.9) |
ECOG = Eastern Cooperative Oncology Group; ETOH = ethanol; HCV = hepatitis C virus; HBV = hepatitis B virus; NASH = nonalcoholic steatohepatitis.
Data are n followed by percentage in parentheses; total n = 185.